Stockreport

UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025

UroGen Pharma Ltd. - Ordinary Shares  (URGN) 
Last urogen pharma ltd. - ordinary shares earnings: 3/2 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.urogen.com
PDF New Drug Application for UGN-102 accepted by US FDA; PDUFA target action date set for June 13, 2025JELMYTO® achieved net product sales of $25.2 million in Q3 2024, compa [Read more]